Ginkgo Bioworks Holdings Q1 2024 GAAP EPS $(0.08) Beats $(0.09) Estimate, Sales $38.000M Miss $46.044M Estimate
Ginkgo Bioworks Holdings Q1 2024 GAAP EPS $(0.08) Beats $(0.09) Estimate, Sales $38.000M Miss $46.044M Estimate
Ginkgo Bioworks Holdings 2024年第一季度GAAP每股收益美元（0.08美元）超过预期（0.09美元），销售额为3,800万美元，低于4604.4万美元的预期
Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. The company reported quarterly sales of $38.000 million which missed the analyst consensus estimate of $46.044 million by 17.47 percent. This is a 52.91 percent decrease over sales of $80.702 million the same period last year.
Ginkgo Bioworks Holdings（纽约证券交易所代码：DNA）公布的季度亏损为每股0.08美元（0.08美元），比分析师普遍预期的0.09美元（0.09美元）高出11.11％。该公司公布的季度销售额为3,800万美元，比分析师普遍预期的4,604.4万美元低17.47％。这比去年同期的8,070.2万美元的销售额下降了52.91％。